Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | CTSL | P07711 | 5/20 | 0.60 |
| ▸ | CTSB | P07858 | 4/20 | 0.60 |
| ▸ | PPID | Q08752 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PPIB | P23284 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | PPIG | Q13427 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19784031 | 0.84 | CTSS (0.52) | CTSSCTSLCTSBPPIDTLR2 | |
| SCHEMBL2913795 | 0.82 | CTSS (0.55) | CTSSCTSLCTSBTLR2CTSK | |
| SCHEMBL3231538 | 0.82 | PPID (0.64) | CTSSCTSLCTSBPPIDCTSK | |
| SCHEMBL6181261 | 0.81 | CTSS (0.89) | CTSSCTSLCTSBCTSK | |
| SCHEMBL14690411 | 0.80 | CTSS (0.53) | CTSSCTSLCTSBTLR2CTSK | |
| Hydrochloric Acid SCHEMBL14690511 | 0.79 | CTSS (0.52) | CTSSCTSLCTSBTLR2CTSK | |
| SCHEMBL22394921 | 0.79 | CTSS (0.60) | CTSSCTSLCTSBTLR2CTSK | |
| SCHEMBL4695521 | 0.79 | PPID (0.51) | CTSSCTSLCTSBPPIDCTSK | |
| SCHEMBL21220066 | 0.79 | CTSS (0.49) | CTSSCTSLCTSBPPIDTLR2 | |
| SCHEMBL14976606 | 0.78 | CTSS (0.56) | CTSSCTSLCTSBTLR2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| CN-1774435-A | 5-membered heterocyclic derivative | DAIICHI SEIYAKU CO (JP) | 2006-05-17 | — | — | CN | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | CTSS 1423/4885CTSL 2195/4885CTSB 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.